Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis
Clinics in Liver Disease · 2026
DOI: 10.1016/j.cld.2026.01.004 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinics in Liver Disease, 2026. Verfasst von Eliabe S Abreu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology & Hepatology, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USA. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Bariatric Surgery, Liver Cirrhosis, Pyridazines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 95 Literaturangaben.
Abstract (Originalsprache)
Metabolic dysfunction-associated steatohepatitis (MASH), the progressive form of metabolic dysfunction-associated steatotic liver disease (MASLD), has historically been treated with lifestyle modification (dietary changes, exercise and weight loss). While lifestyle modification remains foundational in the treatment of MASLD/MASH, resmetirom (a thyroid hormone β-receptor agonist) and semaglutide (a glucagon-like-peptide-1 receptor agonist) are now Food and Drug Administration-approved for patients with MASH and clinically significant hepatic fibrosis (ie, F2-F3 fibrosis). Emerging therapies will allow for future opportunities at a personalized approach to treatment of MASH. This article reviews currently approved and future regimens for the treatment of MASH and MASH-related cirrhosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology & Hepatology, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USA.
- Sherrie and Alan Conover Center for Liver Disease and Transplantation, Houston Methodist Hospital, Houston, TX, USA; Houston Research Institute and Houston Liver Institute, 1155 Dairy Ashford Road, Suite 200, Houston, T…
- Division of Metabolism and Endocrinology, Faculty of Medicine, Liver Center, Saga University Hospital, Saga University, Saga, Japan.
- Department of Internal Medicine II, Saarland University Medical Center, Kirrberger Str. 100, Gebäude 41, 66421 Homburg, Germany.
- Division of Gastroenterology & Hepatology, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USA. Electronic address: abdelmalek.manal@mayo.edu.
Zitieren
APA
Abreu, E. S., Noureddin, M., Takahashi, H., Schattenberg, J. M., & Abdelmalek, M. F. (2026). Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis. Clinics in Liver Disease. https://doi.org/10.1016/j.cld.2026.01.004
Vancouver
Abreu ES, Noureddin M, Takahashi H, Schattenberg JM, Abdelmalek MF. Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis. Clinics in Liver Disease. 2026. doi:10.1016/j.cld.2026.01.004
BibTeX
@article{Abreu2026,
author = {Abreu, Eliabe S and Noureddin, Mazen and Takahashi, Hirokazu and Schattenberg, Jörn M and Abdelmalek, Manal F},
title = {Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis},
journal = {Clinics in Liver Disease},
year = {2026},
doi = {10.1016/j.cld.2026.01.004}
}
EUVIMED